# EDGAR Filing Document

**Accession Number:** 0001372299
**File Stem:** 0001372299-25-000004
**Filing Date:** 2025-6
**Character Count:** 6780
**Document Hash:** 530e4e5a8f7a9e05e203e5602b4bf07c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001372299-25-000004.hdr.sgml**: 20250617

**ACCESSION NUMBER**: 0001372299-25-000004

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 33

**CONFORMED PERIOD OF REPORT**: 20250616

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250617

**DATE AS OF CHANGE**: 20250616

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Ocugen, Inc.
- **CENTRAL INDEX KEY:** 0001372299
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36751
- **FILM NUMBER:** 251051278

**BUSINESS ADDRESS:**
- **STREET 1:** 11 GREAT VALLEY PARKWAY
- **CITY:** MALVERN
- **STATE:** PA
- **ZIP:** 19355
- **BUSINESS PHONE:** 484-328-4701

**MAIL ADDRESS:**
- **STREET 1:** 11 GREAT VALLEY PARKWAY
- **CITY:** MALVERN
- **STATE:** PA
- **ZIP:** 19355

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** HISTOGENICS CORP
- **DATE OF NAME CHANGE:** 20060810

?xml version='1.0' encoding='ASCII'? ocgn-20250616

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

___________________________________________________________

**FORM 8-K**

___________________________________________________________

**CURRENT REPORT**

**Pursuant to Section 13 OR 15 (d)**

**of The Securities Exchange Act of 1934**

Date of Report (Date of Earliest Event Reported): **June 16, 2025**

___________________________________________________________

**OCUGEN, INC.**

(Exact Name of Registrant as Specified in its Charter)

___________________________________________________________

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-36751** | **04-3522315** |
| (State or Other Jurisdiction of <br>Incorporation) | (Commission <br>File Number) | (I.R.S. Employer <br>Identification Number) |

---

**11 Great Valley Parkway**

**Malvern, Pennsylvania 19355**

**(484) 328-4701**

(Address, including zip code, and telephone number, including area code, of principal executive office)

**N/A**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8–K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Soliciting material pursuant to Rule 14a–12 under the Exchange Act (17 CFR 240.14a–12)

☐&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pre–commencement communications pursuant to Rule 14d–2(b) under the Exchange Act (17 CFR 240.14d–2(b))

☐&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pre–commencement communications pursuant to Rule 13e–4(c) under the Exchange Act (17 CFR 240.13e–4(c))

------

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, $0.01 par value per share | OCGN | The Nasdaq Stock Market LLC<br>(The Nasdaq Capital Market) |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 8.01 Other Events.**

Attached as Exhibit 99.1 hereto and incorporated herein by reference is a presentation that Ocugen, Inc. will post on its website on June 16, 2025 and may use from time to time in presentations or discussions with investors, analysts, other parties.

**Item 9.01 Financial Statements and Exhibits.**

The following exhibits are being furnished herewith:

**(d) Exhibits**

---

| | |
|:---|:---|
| **Exhibit No.** | **Document** |
| 99.1 | <u>[Ocugen, Bio Presentation](ocugenincbio6162025.htm)</u> |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 16, 2025

---

| | |
|:---|:---|
| OCUGEN, INC. | OCUGEN, INC. |
| By: | /s/ Shankar Musunuri |
|  | Name: Shankar Musunuri |
|  | Title: Chairman, Chief Executive Officer, & Co-Founder |

---

## Exhibit 99.1

![](ocugenincbio6162025001.jpg)

------

![](ocugenincbio6162025002.jpg)

------

![](ocugenincbio6162025003.jpg)

------

![](ocugenincbio6162025004.jpg)

------

![](ocugenincbio6162025005.jpg)

------

![](ocugenincbio6162025006.jpg)

• •

------

![](ocugenincbio6162025007.jpg)

------

![](ocugenincbio6162025008.jpg)

• • •

------

![](ocugenincbio6162025009.jpg)

Visual Field 0 10 20 30 40 50 60 70 80 P ro p o rt io n o f R e s p o n d e rs 75% 6/8

------

![](ocugenincbio6162025010.jpg)

• • • o ± Year 1 Year 2 -5 0 5 10 M e a n Δ L L V A (± S E M) fr o m B a s e li n e Treated Eye Untreated Eye \* p = 0.005 p = 0.021 \* Year 1 Year 2 -5 0 5 10 M e a n Δ L L V A (± S E M) fr o m B a s e li n e Treated Eye Untreated Eye \* p = 0.005 p = 0.055

------

![](ocugenincbio6162025011.jpg)

------

![](ocugenincbio6162025012.jpg)

• • • •

------

![](ocugenincbio6162025013.jpg)

0.0 0.5 1.0 1.5 12MM e a n C h a n g e (± S E M) i n T o ta l A tr o p h y A re a f ro m B a s e li n e (m m 2) Treated Eye Untreated Eye Baseline M3 M6 M12 -10 -5 0 5 10 M e a n C h a n g e i n B C V A (E T D R S) fr o m B a s e li n e (± S E M) Treated Eye Untreated Eye • • ± ± ± ± ± ± ±

------

![](ocugenincbio6162025014.jpg)

× • • • •

------

![](ocugenincbio6162025015.jpg)

------

![](ocugenincbio6162025016.jpg)

• • • • • • • • • •

------

![](ocugenincbio6162025017.jpg)

• • BL 3M 6M 9M 12M -25 -20 -15 -10 -5 0 5 10 M e a n c h a n g e i n L L V A (E T D R S) fr o m B a s e li n e Treated Eye Untreated Eye ±

------

![](ocugenincbio6162025018.jpg)

------

![](ocugenincbio6162025019.jpg)

------

![](ocugenincbio6162025020.jpg)

------